Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · see citing works

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222 · see citing works

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Ge, D., Fellay, J., Thompson, A. J. V., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,510 · see citing works

Regulation of type I interferon responses

Ivashkiv, L. B., & Donlin, L. T. (2013) · Nature reviews. Immunology · doi:10.1038/nri3581 · Cited by 3,311 · see citing works

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

Ziegler, C. G. K., Allon, S. J., Nyquist, S. K., Mbano, I. M., Miao, V. N., Tzouanas, C. N., Cao, Y., Yousif, A. S., Bals, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.035 · Cited by 2,284 · see citing works

Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus

Kurt-Jones, E., Popova, L., Kwinn, L. A., Haynes, L., Jones, L. P., Tripp, R., Walsh, E., Freeman, M., Golenbock, D., Anderson, L., et al. (2000) · Nature Immunology · doi:10.1038/80833 · Cited by 1,842 · see citing works

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Sheahan, T. P., Sims, A. M., Leist, S. R., Schäfer, A., Won, J. J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D. M., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,726 · see citing works

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. M. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,400 · see citing works

Interferon-stimulated genes and their antiviral effector functions

Schoggins, J. W., & Rice, C. M. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.10.008 · Cited by 1,296 · see citing works

SARS: systematic review of treatment effects

Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217 · see citing works

Shared and Distinct Functions of Type I and Type III Interferons

Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138 · see citing works

Human Coronavirus: Host-Pathogen Interaction

Fung, T. S., & Liu, D. X. (2019) · Annual Review of Microbiology · doi:10.1146/annurev-micro-020518-115759 · Cited by 964 · see citing works

2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members

Daffis, S., Szretter, K. J., Schriewer, J. M., Li, J., Youn, S., Errett, J. S., Lin, T., Schneller, S. W., Züst, R., Dong, H., et al. (2010) · Nature · doi:10.1038/nature09489 · Cited by 910 · see citing works

Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists

Kopecky-Bromberg, S. A., Martínez‐Sobrido, L., Frieman, M. B., Baric, R. S., & Palese, P. (2006) · Journal of Virology · doi:10.1128/jvi.01782-06 · Cited by 662 · see citing works

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

Chan, J. F., Yao, Y., Yeung, M. L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yü, P., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 607 · see citing works

Human Coronaviruses: A Review of Virus–Host Interactions

Lim, Y. X., Ng, Y. W., Tam, J. P., & Liu, D. X. (2016) · Diseases · doi:10.3390/diseases4030026 · Cited by 585 · see citing works

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

Channappanavar, R., Fehr, A. R., Zheng, J. H., Wohlford-Lenane, C., Abrahante, J. E., Mack, M., Sompallae, R. R., McCray, P. B., Meyerholz, D. K., & Perlman, S. M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126363 · Cited by 556 · see citing works

Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi Membrane

Frieman, M. B., Yount, B. L., Heise, M. T., Kopecky-Bromberg, S. A., Palese, P., & Baric, R. S. (2007) · Journal of Virology · doi:10.1128/jvi.01012-07 · Cited by 508 · see citing works

Type 1 interferons as a potential treatment against COVID-19

Sallard, E., Lescure, F.-X., Yazdanpanah, Y., Mentré, F., & Peiffer‐Smadja, N. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104791 · Cited by 508 · see citing works

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study

Omrani, A. S., Saad, M. M., Baig, K. M., Bahloul, A., Abdul-Matin, M., Aidaroos, A. Y. A., Almakhlafi, G. A., Albarrak, M. M., Memish, Z. A., & Albarrak, A. M. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70920-x · Cited by 493 · see citing works

Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection

Totura, A. L., Whitmore, A. C., Agnihothram, S., Schäfer, A., Katze, M. G., Heise, M. T., & Baric, R. S. (2015) · mBio · doi:10.1128/mbio.00638-15 · Cited by 479 · see citing works

Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness

Galani, I. E., Triantafyllia, V., Eleminiadou, E.-E., Koltsida, O., Stavropoulos, A., Manioudaki, M., Thanos, D., Doyle, S. E., Kotenko, S. V., Thanopoulou, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.04.025 · Cited by 464 · see citing works

Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase

Chen, Y. Z., Cai, H., Pan, J., Xiang, N., Tien, P., Ahola, T., & Guo, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808790106 · Cited by 454 · see citing works

Rapid generation of a mouse model for Middle East respiratory syndrome

Zhao, J., Li, K., Wohlford-Lenane, C., Agnihothram, S., Fett, C., Zhao, J., Gale, M., Baric, R. S., Enjuanes, L., Gallagher, T., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323279111 · Cited by 452 · see citing works

Lambda Interferon Renders Epithelial Cells of the Respiratory and Gastrointestinal Tracts Resistant to Viral Infections

Mordstein, M., Neugebauer, E., Ditt, V., Jessen, B., Rieger, T., Falcone, V., Sorgeloos, F., Ehl, S. R., Mayer, D., Kochs, G., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00272-10 · Cited by 447 · see citing works

Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques

Falzarano, D., de Wit, E., Rasmussen, A. L., Feldmann, F., Okumura, A., Scott, D. P., Brining, D., Bushmaker, T., Martellaro, C., Baseler, L. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3362 · Cited by 445 · see citing works

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

Konno, Y., Kimura, I., Uriu, K., Fukushi, M., Irie, T., Koyanagi, Y., Sauter, D., Gifford, R. J., Nakagawa, S., & Sato, K. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108185 · Cited by 433 · see citing works

Antiviral activities of type I interferons to SARS-CoV-2 infection

Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S., & Huang, C. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104811 · Cited by 427 · see citing works

Interferon-α2b Treatment for COVID-19

Zhou, Q., Chen, V., Shannon, C. P., Wei, X.-S., Xiang, X., Wang, X., Wang, Z.-H., Tebbutt, S. J., Kollmann, T. R., & Fish, E. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01061 · Cited by 417 · see citing works

SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon

Totura, A. L., & Baric, R. S. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.04.004 · Cited by 416 · see citing works

Regulation of IRF-3-dependent Innate Immunity by the Papain-like Protease Domain of the Severe Acute Respiratory Syndrome Coronavirus

Devaraj, S. G., Wang, N., Chen, Z., Chen, Z., Tseng, M., Barretto, N., Lin, R., Peters, C. J., Tseng, C.-T. K., Baker, S. C., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704870200 · Cited by 411 · see citing works

Control of coronavirus infection through plasmacytoid dendritic-cell–derived type I interferon

Cervantes‐Barragán, L., Züst, R., Weber, F., Spiegel, M., Lang, K. S., Akira, S., Thiel, V., & Ludewig, B. (2006) · Blood · doi:10.1182/blood-2006-05-023770 · Cited by 397 · see citing works

Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome

Cameron, M. J., Ran, L., Xu, L., Danesh, A., Bermejo-Martin, J. F., Cameron, C. M., Muller, M. P., Gold, W. L., Richardson, S. E., Poutanen, S. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.00527-07 · Cited by 386 · see citing works

Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome

Loutfy, M. R., Blatt, L. M., Siminovitch, K. A., Ward, S. E., Wolff, B., Lho, H., Pham, D. H., Deif, H., LaMere, E. A., Chang, M., et al. (2003) · JAMA · doi:10.1001/jama.290.24.3222 · Cited by 382 · see citing works

Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques

Haagmans, B. L., Kuiken, T., Martina, B. E. E., Fouchier, R. A. M., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D. A. J., de Jong, T., Itamura, S., Chan, K., et al. (2004) · Nature Medicine · doi:10.1038/nm1001 · Cited by 376 · see citing works

The intracellular sites of early replication and budding of SARS-coronavirus

Stertz, S., Reichelt, M., Spiegel, M., Kuri, T., Martínez‐Sobrido, L., García‐Sastre, A., Weber, F., & Kochs, G. (2007) · Virology · doi:10.1016/j.virol.2006.11.027 · Cited by 373 · see citing works

Fundamental properties of the mammalian innate immune system revealed by multispecies comparison of type I interferon responses

Shaw, A. E., Hughes, J., Gu, Q., Behdenna, A., Singer, J. B., Dennis, T. P. W., Orton, R. J., Varela, M., Gifford, R. J., Wilson, S. J., et al. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2004086 · Cited by 341 · see citing works

Severe Acute Respiratory Syndrome Coronavirus Evades Antiviral Signaling: Role of nsp1 and Rational Design of an Attenuated Strain

Wathelet, M. G., Orr, M., Frieman, M. B., & Baric, R. S. (2007) · Journal of Virology · doi:10.1128/jvi.00702-07 · Cited by 339 · see citing works

Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells

Stanifer, M. L., Kee, C., Cortese, M., Metz‐Zumaran, C., Triana, S., Mukenhirn, M., Kraeusslich, H.-G., Alexandrov, T., Bartenschlager, R. F. W., & Boulant, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107863 · Cited by 332 · see citing works

Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates

Smits, S. L., de Lang, A., van den Brand, J. M. A., Leijten, L. M. E., van IJcken, W. F. J., Eijkemans, M. J. C., van Amerongen, G., Kuiken, T., Andeweg, A. C., Osterhaus, A. D. M. E., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000756 · Cited by 331 · see citing works

Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study

Al‐Tawfiq, J. A., Momattin, H., Dib, J. G., & Memish, Z. A. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2013.12.003 · Cited by 322 · see citing works

Pathogenic Influenza Viruses and Coronaviruses Utilize Similar and Contrasting Approaches To Control Interferon-Stimulated Gene Responses

Menachery, V. D., Eisfeld, A. J., Schäfer, A., Josset, L., Sims, A. M., Proll, S. C., Fan, S., Li, C., Neumann, G., Tilton, S. C., et al. (2014) · mBio · doi:10.1128/mbio.01174-14 · Cited by 307 · see citing works

Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome

Reghunathan, R., Jayapal, M., Hsu, L. Y., Chng, H. H., Tai, D. Y. H., Leung, B. P. L., & Melendez, A. J. (2005) · BMC Immunology · doi:10.1186/1471-2172-6-2 · Cited by 295 · see citing works

Severe Acute Respiratory Syndrome Coronavirus M Protein Inhibits Type I Interferon Production by Impeding the Formation of TRAF3·TANK·TBK1/IKKϵ Complex

Siu, K., Kok, K., Ng, M.-H. J., Poon, V. K., Yuen, K., Zheng, B.-J., & Jin, D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.008227 · Cited by 273 · see citing works

The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists

Yang, Y., Zhang, L., Geng, H., Deng, Y. L., Huang, B., Yin, G., Zhao, Z., & Tan, W. (2013) · Protein & Cell · doi:10.1007/s13238-013-3096-8 · Cited by 273 · see citing works

Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune Responses Elicited by Type I and Type III Interferons

Forero, A., Ozarkar, S., Li, H., Lee, C. H., Hemann, E. A., Nadjsombati, M. S., Hendricks, M. R., So, L., Green, R. R., Roy, C. N., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.07.007 · Cited by 269 · see citing works

IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission

Klinkhammer, J., Schnepf, D., Ye, L., et al. (2018) · eLife · doi:10.7554/elife.33354 · Cited by 265 · see citing works

The Immunobiology of SARS

Chen, J., & Subbarao, K. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141706 · Cited by 252 · see citing works

IFNλ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFNα treatment

Davidson, S., McCabe, T. M., Crotta, S., Gad, H. H., Hessel, E. M., Beinke, S., Hartmann, R., & Wack, A. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606413 · Cited by 240 · see citing works

SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism

Lu, X., Pan, J., Tao, J., & Guo, D. (2010) · Virus Genes · doi:10.1007/s11262-010-0544-x · Cited by 236 · see citing works

Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections

Nelemans, T., & Kikkert, M. (2019) · Viruses · doi:10.3390/v11100961 · Cited by 224 · see citing works

A Virological View of Innate Immune Recognition

Iwasaki, A. (2012) · Annual Review of Microbiology · doi:10.1146/annurev-micro-092611-150203 · Cited by 213 · see citing works

Attenuation and Restoration of Severe Acute Respiratory Syndrome Coronavirus Mutant Lacking 2′-O-Methyltransferase Activity

Menachery, V. D., Yount, B. L., Josset, L., Gralinski, L. E., Scobey, T., Agnihothram, S., Katze, M. G., & Baric, R. S. (2014) · Journal of Virology · doi:10.1128/jvi.03571-13 · Cited by 213 · see citing works

MyD88 Is Required for Protection from Lethal Infection with a Mouse-Adapted SARS-CoV

Sheahan, T. P., Morrison, T. E., Funkhouser, W., Uematsu, S., Akira, S., Baric, R. S., & Heise, M. T. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000240 · Cited by 207 · see citing works

Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection

Kim, E. S., Choe, P. G., Park, W. B., Oh, H. S., Kim, E. J., Nam, E. Y., Na, S. H., Kim, M., Song, K., Bang, J. H., et al. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.11.1717 · Cited by 193 · see citing works

IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study

Shalhoub, S., Farahat, F. M., Al-Jiffri, A. M. Y., Simhairi, R., Shamma, O., Siddiqi, N., & Mushtaq, A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv085 · Cited by 190 · see citing works

Dynamic Innate Immune Responses of Human Bronchial Epithelial Cells to Severe Acute Respiratory Syndrome-Associated Coronavirus Infection

Yoshikawa, T., Hill, T. E., Yoshikawa, N., Popov, V. L., Galindo, C. L., Garner, H. R., Peters, C. J., & Tseng, C.-T. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008729 · Cited by 187 · see citing works

SARS-CoV Pathogenesis Is Regulated by a STAT1 Dependent but a Type I, II and III Interferon Receptor Independent Mechanism

Frieman, M. B., Chen, J., Morrison, T. E., Whitmore, A., Funkhouser, W., Ward, J. M., Lamirande, E. W., Roberts, A., Heise, M., Subbarao, K., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000849 · Cited by 158 · see citing works

Aging impairs both primary and secondary RIG-I signaling for interferon induction in human monocytes

Molony, R. D., Nguyen, J. T., Kong, Y., Montgomery, R. R., Shaw, A. C., & Iwasaki, A. (2017) · Science Signaling · doi:10.1126/scisignal.aan2392 · Cited by 154 · see citing works

Middle East Respiratory Syndrome Coronavirus NS4b Protein Inhibits Host RNase L Activation

Thornbrough, J. M., Jha, B. K., Yount, B. L., Goldstein, S. A., Li, Y., Elliott, R., Sims, A. M., Baric, R. S., Silverman, R. H., & Weiss, S. R. (2016) · mBio · doi:10.1128/mbio.00258-16 · Cited by 149 · see citing works

Intranasal Treatment with Poly(I·C) Protects Aged Mice from Lethal Respiratory Virus Infections

Zhao, J., Wohlford-Lenane, C., Zhao, J., Fleming, E., Lane, T. E., McCray, P. B., & Perlman, S. M. (2012) · Journal of Virology · doi:10.1128/jvi.01410-12 · Cited by 140 · see citing works

Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial

and the Saudi Critical Care Trials group, Arabi, Y. M., Asiri, A. Y., Assiri, A. M., Jokhdar, H., Alothman, A. F., Balkhy, H. H., AlJohani, S. M., Harbi, S. A. A., Kojan, S. M., et al. (2020) · Trials · doi:10.1186/s13063-019-3846-x · Cited by 128 · see citing works

Murine Coronavirus Induces Type I Interferon in Oligodendrocytes through Recognition by RIG-I and MDA5

Li, J., Liu, Y., & Zhang, X. (2010) · Journal of Virology · doi:10.1128/jvi.00016-10 · Cited by 126 · see citing works

High Secretion of Interferons by Human Plasmacytoid Dendritic Cells upon Recognition of Middle East Respiratory Syndrome Coronavirus

Scheuplein, V., Seifried, J., Malczyk, A. H., Miller, L., Höcker, L., Vergara‐Alert, J., Dolnik, O., Zielecki, F., Becker, B., Spreitzer, I., et al. (2015) · Journal of Virology · doi:10.1128/jvi.03607-14 · Cited by 123 · see citing works

Type III IFNs: Beyond antiviral protection

Kotenko, S. V., Rivera, A., Parker, D., & Durbin, J. E. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101303 · Cited by 120 · see citing works

Middle East Respiratory Syndrome Coronavirus Nonstructural Protein 16 Is Necessary for Interferon Resistance and Viral Pathogenesis

Menachery, V. D., Gralinski, L. E., Mitchell, H. D., Dinnon, K. H., Leist, S. R., Yount, B. L., Graham, R. L., McAnarney, E. T., Stratton, K. G., Cockrell, A. S., et al. (2017) · mSphere · doi:10.1128/msphere.00346-17 · Cited by 101 · see citing works

Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus

Sutton, T. C., & Subbarao, K. (2015) · Virology · doi:10.1016/j.virol.2015.02.030 · Cited by 97 · see citing works

Toll-Like Receptor 4 Deficiency Increases Disease and Mortality after Mouse Hepatitis Virus Type 1 Infection of Susceptible C3H Mice

Khanolkar, A., Hartwig, S. M., Haag, B. A., Meyerholz, D. K., Harty, J. T., & Varga, S. M. (2009) · Journal of Virology · doi:10.1128/jvi.01857-08 · Cited by 60 · see citing works

The Superiority of IFN-λ as a Therapeutic Candidate to Control Acute Influenza Viral Lung Infection

Kim, S.-J., Kim, M., Kim, C., Kang, J. W., Shin, H. K., Kim, D., Won, T., Han, D. H., Rhee, C., Yoon, J., et al. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0174oc · Cited by 59 · see citing works

Combined action of type I and type III interferon restricts initial replication of severe acute respiratory syndrome coronavirus in the lung but fails to inhibit systemic virus spread

Mahlakõiv, T., Ritz, D., Mordstein, M., DeDiego, M. L., Enjuanes, L., Müller, M. A., Drosten, C., & Staeheli, P. (2012) · Journal of General Virology · doi:10.1099/vir.0.046284-0 · Cited by 58 · see citing works

Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol® (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model

Kumaki, Y., Salazar, A. Μ., Wandersee, M. K., & Barnard, D. L. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.12.007 · Cited by 56 · see citing works

Transcriptomic Analysis Reveals a Mechanism for a Prefibrotic Phenotype in STAT1 Knockout Mice during Severe Acute Respiratory Syndrome Coronavirus Infection

Zornetzer, G. A., Frieman, M. B., Rosenzweig, E., Korth, M. J., Page, C., Baric, R. S., & Katze, M. G. (2010) · Journal of Virology · doi:10.1128/jvi.01130-10 · Cited by 48 · see citing works

Evasion of Type I Interferon by SARS-CoV-2

Xia, H., Cao, Z., Xie, X., Zhang, X., Chen, J. Y.-C., Wang, H., Menachery, V. D., Rajsbaum, R., & Shi, P.-Y. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108234 · Cited by 957 · see citing works

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Winkler, E. S., Bailey, A. L., Kafai, N. M., Nair, S., McCune, B. T., Yu, J., Fox, J. M., Chen, R. E., Earnest, J. T., Keeler, S. P., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0778-2 · Cited by 901 · see citing works

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560 · see citing works

The cGAS–STING pathway drives type I IFN immunopathology in COVID-19

Domizio, J. D., Gulen, M. F., Saidoune, F., Thacker, V. V., Yatim, A., Sharma, K., Nass, T., Guenova, E., Schaller, M., Conrad, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04421-w · Cited by 538 · see citing works

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

Israelow, B., Song, E., Mao, T., Lu, P., Meir, A., Liu, F., Alfajaro, M. M., Wei, J., Dong, H., Homer, R. J., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201241 · Cited by 415 · see citing works

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

Konno, Y., Kimura, I., Uriu, K., Fukushi, M., Irie, T., Koyanagi, Y., Sauter, D., Gifford, R. J., Nakagawa, S., & Sato, K. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108185 · Cited by 433 · see citing works

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling

Zheng, Y., Zhuang, M.-W., Han, L., Zhang, J., Nan, M.-L., Zhan, P., Kang, D., Liu, X., Gao, C., & Wang, P.-H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00438-7 · Cited by 302 · see citing works

Three-dimensional human alveolar stem cell culture models reveal infection response to SARS-CoV-2

Youk, J., Kim, T., Evans, K. V., Jeong, Y.-I., Hur, Y., Hong, S. P., Kim, J. H., Yi, K., Kim, S. Y., Na, K. J., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.10.004 · Cited by 266 · see citing works

SARS-CoV-2 spreads through cell-to-cell transmission

Zeng, C., Evans, J. P., King, T., Zheng, Y.-M., Oltz, E. M., Whelan, S. P. J., Saif, L. J., Peeples, M. E., & Liu, S.-L. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111400119 · Cited by 246 · see citing works

Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2

Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl4509 · Cited by 189 · see citing works

Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2

Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021) · doi:10.1101/2021.05.19.444825 · Cited by 189 · see citing works

Approaches and Challenges in SARS-CoV-2 Vaccine Development

Dagotto, G., Yu, J., & Barouch, D. H. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.08.002 · Cited by 103 · see citing works

IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection

Rosa, B. A., Ahmed, M., Singh, D. K., Choreño-Parra, J. A., Cole, J., Jiménez-Álvarez, L. A., Rodríguez-Reyna, T. S., Singh, B., Gonzalez, O., Carrion, R., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01829-4 · Cited by 106 · see citing works

COVID-19: neonatal–perinatal perspectives

On behalf of the Harvard Neonatal-Perinatal Fellowship COVID-19 Working Group, Barrero-Castillero, A., Beam, K. S., Bernardini, L. B., Ramos, E. G. C., Davenport, P. E., Duncan, A. R., Fraiman, Y. S., Frazer, L. C., Healy, H., et al. (2021) · Journal of Perinatology · doi:10.1038/s41372-020-00874-x · Cited by 92 · see citing works

Age‐related differences in the immune response could contribute to determine the spectrum of severity of COVID‐19

Costagliola, G., Spada, E., & Consolini, R. (2021) · Immunity, Inflammation and Disease · doi:10.1002/iid3.404 · Cited by 81 · see citing works

SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release

Junqueira, C., Crespo, Â., Ranjbar, S., Ingber, J., Parry, B., Ravid, S., Lacerda, L. B. D., Lewandrowski, M., Clark, S., Ho, F., et al. (2021) · doi:10.1101/2021.03.06.21252796 · Cited by 70 · see citing works